A patient with a non-sex-specific solid tumor is being considered for curative-intent local therapy with an immune checkpoint inhibitor. The oncology team asks what this meta-analysis suggests about ICI timing and whether sex changes expected survival benefit.
Which conclusion is best supported by the evidence in this abstract?
